Sage Therapeutics (SAGE) News Today $5.10 -0.27 (-5.03%) (As of 11/15/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Investment surges, hurdles and emerging innovations in neuroscienceNovember 11, 2024 | finance.yahoo.comEasterly Investment Partners LLC Has $326,000 Holdings in Sage Therapeutics, Inc. (NASDAQ:SAGE)Easterly Investment Partners LLC reduced its position in Sage Therapeutics, Inc. (NASDAQ:SAGE - Free Report) by 67.0% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 45,102 shares of thNovember 9, 2024 | marketbeat.comJ.P. Morgan Sticks to Its Hold Rating for SAGE Therapeutics (SAGE)November 8, 2024 | markets.businessinsider.comSage Therapeutics price target lowered to $9 from $11 at Morgan StanleyNovember 5, 2024 | markets.businessinsider.comSAGE Therapeutics: Balancing Promising Sales Growth with Strategic Uncertainties – A Hold RatingNovember 5, 2024 | markets.businessinsider.comSage Therapeutics, Inc. (NASDAQ:SAGE) Position Reduced by Pinnacle Associates Ltd.Pinnacle Associates Ltd. trimmed its stake in shares of Sage Therapeutics, Inc. (NASDAQ:SAGE - Free Report) by 42.5% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 168,573 shares of the biopharmaceutical company's stocNovember 2, 2024 | marketbeat.comCambridge biotech's layoffs will cut dozens of Mass. employeesNovember 1, 2024 | bizjournals.comSAGE Therapeutics Announces Strategic Reorganization Amid Executive DeparturesNovember 1, 2024 | markets.businessinsider.comHC Wainwright Has Bearish Estimate for SAGE FY2024 EarningsSage Therapeutics, Inc. (NASDAQ:SAGE - Free Report) - Investment analysts at HC Wainwright reduced their FY2024 earnings estimates for shares of Sage Therapeutics in a research report issued to clients and investors on Wednesday, October 30th. HC Wainwright analyst D. Tsao now forecasts that theNovember 1, 2024 | marketbeat.comHold Rating on Sage Therapeutics Amid Promising Revenue but Uncertain Future ExpensesNovember 1, 2024 | markets.businessinsider.comHold Rating Maintained for SAGE Therapeutics Amid Positive Sales and Strategic ChallengesOctober 31, 2024 | markets.businessinsider.comStifel Nicolaus Remains a Hold on SAGE Therapeutics (SAGE)October 31, 2024 | markets.businessinsider.comSage Therapeutics price target lowered to $26 from $52 at Piper SandlerOctober 31, 2024 | finance.yahoo.comWhat is HC Wainwright's Estimate for SAGE FY2028 Earnings?Sage Therapeutics, Inc. (NASDAQ:SAGE - Free Report) - HC Wainwright reduced their FY2028 earnings per share (EPS) estimates for shares of Sage Therapeutics in a research note issued on Wednesday, October 30th. HC Wainwright analyst D. Tsao now anticipates that the biopharmaceutical company will eOctober 31, 2024 | marketbeat.comSage Therapeutics Reports Q3 Growth and Strategic FocusOctober 31, 2024 | msn.comSage Therapeutics Inc (SAGE) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid ...October 31, 2024 | finance.yahoo.comHold Rating on SAGE Therapeutics Amid Promising Developments and Strategic UncertaintiesOctober 31, 2024 | markets.businessinsider.comSage Therapeutics price target lowered to $14 from $17 at ScotiabankOctober 31, 2024 | markets.businessinsider.comScotiabank Lowers Sage Therapeutics (NASDAQ:SAGE) Price Target to $14.00Scotiabank cut their price target on shares of Sage Therapeutics from $17.00 to $14.00 and set a "sector outperform" rating on the stock in a research report on Wednesday.October 30, 2024 | marketbeat.comPiper Sandler Reiterates "Overweight" Rating for Sage Therapeutics (NASDAQ:SAGE)Piper Sandler restated an "overweight" rating and set a $26.00 price target (down from $52.00) on shares of Sage Therapeutics in a research report on Wednesday.October 30, 2024 | marketbeat.comHold Rating on SAGE Therapeutics Amid Strong Zurzuvae Demand and Strategic ShiftsOctober 30, 2024 | markets.businessinsider.comSage Therapeutics Announces Third Quarter 2024 Financial Results and Highlights Pipeline and Business UpdatesOctober 30, 2024 | stockhouse.comSage stock plunges 18% post-market following business update, earningsOctober 30, 2024 | msn.comHold Rating on SAGE Therapeutics Due to Stable Performance and High-Risk ProspectsOctober 30, 2024 | markets.businessinsider.comSage to sunset first postpartum depression drug, focus on ZurzuvaeOctober 30, 2024 | bizjournals.comSage Therapeutics (NASDAQ:SAGE) Posts Earnings Results, Meets EstimatesSage Therapeutics (NASDAQ:SAGE - Get Free Report) announced its earnings results on Tuesday. The biopharmaceutical company reported ($1.53) EPS for the quarter, meeting the consensus estimate of ($1.53). The company had revenue of $11.87 million during the quarter, compared to the consensus estimate of $10.80 million. Sage Therapeutics had a negative net margin of 458.30% and a negative return on equity of 55.87%. The firm's revenue for the quarter was up 337.1% on a year-over-year basis. During the same quarter in the prior year, the company posted ($2.81) earnings per share.October 29, 2024 | marketbeat.comSage Therapeutics, Inc. (NASDAQ:SAGE) Receives Average Rating of "Reduce" from BrokeragesSage Therapeutics, Inc. (NASDAQ:SAGE - Get Free Report) has earned an average rating of "Reduce" from the twenty research firms that are covering the stock, MarketBeat reports. Two analysts have rated the stock with a sell rating, seventeen have issued a hold rating and one has assigned a buy raOctober 29, 2024 | marketbeat.comFINAL SAGE DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Sage Therapeutics, Inc. Investors to Join the Class Action Lawsuit!October 28, 2024 | markets.businessinsider.comSage Therapeutics's Earnings: A PreviewOctober 28, 2024 | benzinga.comSAGE SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Sage Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!October 28, 2024 | globenewswire.comSage Therapeutics Inc Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SAGEOctober 28, 2024 | prnewswire.comSAGE Investors Have Opportunity to Lead Sage Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law FirmOctober 28, 2024 | prnewswire.comShareholders that lost money on Sage Therapeutics, Inc.(SAGE) should contact The Gross Law Firm about pending Class Action - SAGEOctober 28, 2024 | prnewswire.comSAGE DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Encourages Sage Therapeutics, Inc. Investors to Secure Counsel Before Important October 28 Deadline in Securities Class Action - SAGEOctober 27, 2024 | markets.businessinsider.comSAGE Investors Have Opportunity to Lead Sage Therapeutics, Inc. Securities Fraud LawsuitOctober 26, 2024 | prnewswire.comSAGE DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Sage Therapeutics, Inc. Investors to Secure Counsel Before Important October 28 Deadline in Securities Class Action – SAGEOctober 25, 2024 | globenewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Sage Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - SAGEOctober 25, 2024 | prnewswire.comSHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sage TherapeuticsOctober 25, 2024 | prnewswire.comSAGE Investors Have Opportunity to Lead Sage Therapeutics, Inc. Securities Fraud LawsuitOctober 24, 2024 | prnewswire.comSage Therapeutics, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. October 28, 2024 Deadline to file Lead Plaintiff MotionOctober 23, 2024 | globenewswire.comInvestors who lost money on Sage Therapeutics, Inc. (SAGE) should contact The Gross Law Firm about pending Class Action - SAGEOctober 23, 2024 | globenewswire.comSage Therapeutics Inc Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SAGEOctober 23, 2024 | prnewswire.comSage Therapeutics, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before October 28, 2024 to Discuss Your Rights - SAGEOctober 23, 2024 | prnewswire.comSAGE Investors Have Opportunity to Lead Sage Therapeutics, Inc. Securities Fraud LawsuitOctober 22, 2024 | prnewswire.comSAGE DEADLINE NOTICE: Rosen, A HIGHLY RECOGNIZED LAW FIRM, Encourages Sage Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important October 28 Deadline in Securities Class Action – SAGEOctober 22, 2024 | globenewswire.comSAGE SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Sage Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!October 22, 2024 | globenewswire.comSage Therapeutics, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. October 28, 2024 Deadline to file Lead Plaintiff MotionOctober 21, 2024 | globenewswire.comSAGE Investors Have Opportunity to Lead Sage Therapeutics, Inc. Securities Fraud LawsuitOctober 21, 2024 | prnewswire.comCautious Outlook on SAGE Therapeutics Amid Strategic Reorganization and Uncertain Pipeline PrioritizationOctober 21, 2024 | markets.businessinsider.comSAGE Investors Have Opportunity to Lead Sage Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law FirmOctober 21, 2024 | prnewswire.com Get Sage Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SAGE and its competitors with MarketBeat's FREE daily newsletter. Email Address “This Changes Everything” - Trump Hands Millions Massive IRS Gift (Ad)Now it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as we wait for Trump's agenda to kick in… >> YES! Send Me My FREE Gold Guide! SAGE Media Mentions By Week SAGE Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SAGE News Sentiment▼0.850.55▲Average Medical News Sentiment SAGE News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SAGE Articles This Week▼28▲SAGE Articles Average Week Get Sage Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SAGE and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Emergent BioSolutions News Today Schrödinger News Today Avadel Pharmaceuticals News Today Gyre Therapeutics News Today Arcus Biosciences News Today Travere Therapeutics News Today Ardelyx News Today Kura Oncology News Today Bicara Therapeutics News Today Praxis Precision Medicines News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:SAGE) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sage Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sage Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free SAGE Stock Alerts